Original Research
Published on 16 Nov 2021
Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
in Drugs Outcomes Research and Policies
- 5,598 views
- 35 citations













